IFN-α mediates the up-regulation of HLA class I on melanoma cells without switching proteasome to immunoproteasome

Giuliana Cangemi, Barbara Morandi, Antonella D'Agostino, Cristiano Peri, Romana Conte, Gianluca Damonte, Guido Ferlazzo, Roberto Biassoni, Giovanni Melioli

Research output: Contribution to journalArticle


Treatment of melanoma cell lines with IFN-γ induces the switch from proteasome (PS) to immunoproteasome (iPS). This finding has profound implications for the immunobiology of melanoma cells since certain peptides (such as Melan-Amart1 27-35) are cleaved differently by iPS, thus implying a different ability to be presented by HLA class I molecules. IFN-α is a cytokine not only produced during infectious diseases, but also used in the treatment of certain cancers. Nevertheless, the effects of IFN-α on the switch of PS to WS are largely unknown. A comparison of the effect of both IFN-α and IFN-γ was thus carried out on melanoma cell lines. RT-PCR showed that mRNA for iPS subunits (i.e. LMP-2, LMP-7 and MECL-1) was detectable both in untreated and IFN-treated melanoma cells. Immunoblotting analysis revealed that while IFN-γ was able to consistently induce the switch from PS to iPS, IFN-α treatment did not, possibly due to post-transcriptional event(s) blocking the expression of iPS-specific subunits. Finally, Melan-Amart1 27-35 peptide was found only in the HPLC-MS spectra from both untreated and IFN-α-treated cells, but not upon IFN-γ treatment. Altogether, these data demonstrate that IFN-α does not induce the switch from PS to iPS.

Original languageEnglish
Pages (from-to)1415-1421
Number of pages7
JournalInternational Immunology
Issue number12
Publication statusPublished - Dec 2003



  • HLA
  • IFN
  • Peptide
  • Proteasome

ASJC Scopus subject areas

  • Immunology

Cite this